HLS Therapeutics’ $125 Million Credit Facilities

Cravath represented the borrower, HLS Therapeutics Inc., in connection with the arrangement of its $125 million credit facilities provided by JPMorgan Chase Bank, N.A., to be used for working capital and other general corporate purposes.

HLS Therapeutics Inc. is an acquirer and distributor of pharmaceutical products in North America. The facilities consisted of a $100 million term commitment and a $25 million revolving credit facility. The transaction closed on August 15, 2018.

The Cravath team included partner Stephen M. Kessing (Picture) and associates James J. Valenza and P. Purun Cheong. Summer associate Harold C. King also worked on this matter.

Involved fees earner: Stephen Kessing – Cravath Swaine & Moore; James Valenza – Cravath Swaine & Moore; Purun Cheong – Cravath Swaine & Moore;

Law Firms: Cravath Swaine & Moore;

Clients: HLS Therapeutics;


Author: Ambrogio Visconti